Resumo

DE IZAGUIRRE DE ARELLANO, Jacqueline  e  ECHEZURIA, Luis. VPH. Arch Venez Puer Ped [online]. 2011, vol.74, n.4, pp.159-162. ISSN 0004-0649.

The Food and Drug Administration (FDA) of USA licensed two vaccines for the prevention of VPH (Human Papillomavirus) infection: Gardasil® (quadrivalent vaccine) and Cervarix® (bivalent vaccine). Both vaccines are very effective in the prevention of persistent infection by serotypes 16 and 18 of VPH, two of the “High Risk” VPH, which cause 70% of cervical cancers and in low percentages anal and penile cancers. Gardasil® prevents infection by serotytpes 6 and 11, which cause almost all (90%) of genital warts. This review presents the immunogenicity, efficacy, recommendations, doses, administration and commercial presentation of both vaccines.

Palavras-chave : Vaccines; Gardasil; Cervarix; cervical cancer; penile cancer; anal cancer genital warts.